Iretig

Mirabegron, the active ingredient in Iretig, is a β3‑adrenergic receptor agonist presented as an oral tablet for oral use. It is indicated for the management of overactive bladder symptoms such as urgency, frequency, and urge incontinence in adults.

GNH USA supplies Iretig as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirabegron acts on the β3‑adrenergic pathway to improve bladder storage function. - Overactive bladder: increases bladder capacity and reduces episodes of urgency. - Urinary urgency: lessens the sudden need to void. - Urinary frequency: decreases the number of daily voids.

Adverse reactions may occur with mirabegron therapy.

Common Side Effects: - Hypertension: elevated blood pressure readings. - Nasopharyngitis: mild upper respiratory tract infection. - Headache: transient cranial pain. - Dry mouth: reduced salivary flow. - Constipation: decreased bowel movements. - Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects: - Urinary retention: difficulty initiating or maintaining urine flow. - Severe hypertension: markedly high blood pressure requiring medical attention. - Cardiac arrhythmias: irregular heart rhythms observed in rare cases. - Angioedema: swelling of face, lips, or throat. - Severe allergic reaction: rash, itching, or anaphylaxis. - Liver enzyme elevation: abnormal hepatic function tests.

Patients should be aware of specific safety considerations before starting mirabegron. - Blood pressure monitoring: check baseline and periodic readings. - Cardiovascular disease: assess risk before use. - Drug interactions: review concomitant medications for potential effects on blood pressure. - Renal impairment: adjust therapy based on kidney function. - Pregnancy and lactation: avoid use unless benefits outweigh risks. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Mirabegron may affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - CYP2D6 substrates (e.g., metoprolol): may increase plasma levels. - Antihypertensives (e.g., ACE inhibitors): additive blood pressure effects.

Moderate Interactions (Monitor Closely): - Anticholinergics (e.g., oxybutynin): may reduce efficacy of mirabegron. - Diuretics: potential for altered fluid balance. - NSAIDs: increased risk of hypertension. - Digoxin: possible increase in serum concentration. - CYP3A4 inhibitors (e.g., ketoconazole): may raise mirabegron exposure.